Compare Summit Therapeutics Inc (SMMT) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while State Street SPDR S&P Homebuilders ETF trades at $94.83 (market cap $1.49B). The key difference: Summit Therapeutics Inc is far larger — about 9.2× State Street SPDR S&P Homebuilders ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| SMMT | XHB | |
|---|---|---|
Market Cap | $13.71B | $1.49B |
Volume | 6,173,057 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.38 | $121.36 |
52-Week Low | $12.43 | $94.86 |
Typical Hold Time | 16 Days | 33 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.99, showing minimal daily change. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but shows potential from recent housing policy support and institutional interest.
The outlook for XHB is mixed, balancing sector challenges like rising rates against catalysts such as new housing legislation. Investment opportunity hinges on a housing market rebound, while risks include economic sensitivity and rate volatility. Investor sentiment is cautious but attentive to policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
